Semaglutide: A Promising Ally Against Alzheimer’s?
In a groundbreaking study, researchers at Case Western Reserve School of Medicine have identified a potential new benefit of semaglutide, a widely used diabetes and weight-loss drug. According to their findings, semaglutide may significantly reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes (T2D), outperforming seven other anti-diabetic medications.
Alzheimer’s disease, a devastating brain disorder that erodes memory and cognitive abilities, affects nearly 7 million Americans aged 65 and older, as reported by the Alzheimer’s Association. Alarmingly, it claims more lives annually than breast and prostate cancer combined.
Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study suggests that T2D patients taking semaglutide had a markedly lower risk of developing Alzheimer’s disease. This trend was consistent across various subgroups, regardless of obesity status, gender, or age.
Semaglutide, a glucagon-like peptide receptor (GLP-1R) agonist, is the active ingredient in popular medications like Wegovy and Ozempic. It works by reducing hunger and regulating blood sugar levels in T2D patients.
Under the leadership of Rong Xu, a professor of biomedical informatics, the research team analyzed three years of electronic health records from nearly one million U.S. patients with T2D. Their statistical approach, which mimicked a randomized clinical trial, revealed that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s compared to those on other anti-diabetic medications.
According to the CDC, Alzheimer’s disease results in approximately 120,000 deaths annually, ranking as the seventh-leading cause of death in the United States.
“This new study provides real-world evidence for semaglutide’s potential impact on Alzheimer’s disease,” Xu stated. “While preclinical research has hinted at its protective effects against neurodegeneration and neuroinflammation, our findings suggest the need for further exploration through randomized clinical trials.”
Despite these promising results, the study’s limitations prevent researchers from drawing definitive causal conclusions. Xu emphasized the importance of continued research into semaglutide’s potential as a treatment for this debilitating condition, encouraging further investigation into alternative drugs.
For more information, please contact Patty Zamora at [email protected].
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Commercial real estate deal activity dipped in October for the first time since early 2024, signaling a widening disconnect between buyer and seller pricing expectations in a high‑rate environment. While overall sales remain strong—and even above 2024 levels—the sharp slowdown in momentum highlights rising caution across sectors. Multifamily saw a steep 27% drop in volume, hospitality was the lone sector to grow, and institutional buyers are increasingly targeting discounted office assets. With mortgage originations rebounding but lenders staying selective, 2026 will hinge on how quickly the market aligns on pricing and capital costs.
New Vanguard research reveals that the real impact of financial advisors goes far beyond market performance. Investors say the greatest value comes from peace of mind, personalized planning, emotional reassurance, and the time saved by having a trusted expert manage their financial life. The study highlights a major shift in what clients truly want: confidence, clarity, and guidance that aligns with their personal definition of financial success.
U.S. self‑storage deals surged nearly $1.6 billion in Q3 2025, marking a 62% year‑over‑year jump and the sector’s strongest resurgence in years. REITs paid steep premiums to lock down top‑tier, land‑restricted markets, while states like Florida, California, and Georgia led all sales. New York City dominated with record‑high pricing of $526 per square foot, underscoring the asset class’s resilience and the renewed appetite for specialty commercial investments heading into 2026.
Nearly half a million Florida homeowners are finally seeing relief as Citizens Insurance plans to reduce premiums by up to 11%. After years of rising costs and limited coverage options, the insurer’s shrinking policy load and reduced risk are allowing meaningful savings—averaging about $400 per year for most customers. With several private carriers also lowering rates, experts say this could mark the beginning of a long‑needed stabilization in Florida’s insurance and real estate markets.
Colorado heads into 2026 with steady economic strength despite slowing population growth. The latest forecast from the Leeds School of Business projects 17,500 new jobs, rising incomes, and GDP growth outpacing the national average. Most major industries will expand, even as migration slows and labor shortages persist.
Layoffs across tech, energy, retail, aviation, and education are redefining the 2025 workforce as companies cut costs and accelerate their adoption of AI. Major employers like Amazon, Meta, UPS, and Chevron are restructuring thousands of roles, signaling one of the most significant employment shifts in years. But while traditional positions shrink, demand is rising in fields tied to AI, data, cybersecurity, compliance, and licensed professions. For workers willing to reskill or pivot—especially into areas like real estate, insurance, finance, or other certification‑based careers—new opportunities continue to grow despite the turbulence.
